Citazione APA

Balijepalli, C., Shirali, R., Kandaswamy, P., Ustyugova, A., Pfarr, E., Lund, S. S., & Druyts, E. (2018). Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons. Diabetes Ther.

Stile di citazione Chicago

Balijepalli, Chakrapani, Rohan Shirali, Prashanth Kandaswamy, Anastasia Ustyugova, Egon Pfarr, Søren S. Lund, e Eric Druyts. "Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons." Diabetes Ther 2018.

Citazione MLA

Balijepalli, Chakrapani, et al. "Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons." Diabetes Ther 2018.

Attenzione: Queste citazioni potrebbero non essere precise al 100%.